Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group.
Jensik
S C
SC
Transplant Center, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois 60612, USA.
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006085:Graft Survival / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008074:Lipoproteins / Q000097:blood; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D008074:Lipoproteins; D016853:Muromonab-CD3; D014280:Triglycerides; D016572:Cyclosporine; D002784:Cholesterol; D001379:Azathioprine; D016559:Tacrolimus